scholarly journals Anti-Cancer Drug Screening with Microfluidic Technology

2021 ◽  
Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad
Keyword(s):  
Drug Screening ◽  
Animal Studies ◽  
Ethical Issues ◽  
Cancer Drug ◽  
Screening Methods ◽  
Microfluidic Chips ◽  
Microfluidic Systems ◽  
Microfluidic Technology ◽  
Anti Cancer ◽  
Clinical Experiments

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high throughput drug screening, require a small amount of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. So many attempts were performed in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.

scholarly journals Anti-Cancer Drug Screening with Microfluidic Technology

2021 ◽  
Vol 11 (20) ◽  
pp. 9418
Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad
Keyword(s):  
Drug Screening ◽  
Animal Studies ◽  
Ethical Issues ◽  
Cancer Drug ◽  
Screening Methods ◽  
Microfluidic Chips ◽  
Microfluidic Systems ◽  
Microfluidic Technology ◽  
Anti Cancer ◽  
Clinical Experiments

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high-throughput drug screening, require a small number of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. Many attempts have been made in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.

Microfluidic Cell Arrays to Mimic 3D Tissue Microenvironment

2012 ◽  
Author(s):  
Zeynep Dereli-Korkut ◽  
Sihong Wang
Keyword(s):  
Signaling Pathways ◽  
High Throughput ◽  
Drug Screening ◽  
Complex Disease ◽  
Cancer Drug ◽  
Screening Methods ◽  
Cell Array ◽  
Apoptotic Signaling ◽  
3D Microenvironment ◽  
Anti Cancer

We developed a functional high throughput 3D microfluidic living cell array (MLC) for anti-cancer drug screening and mechanism discovery. Contemporary drug screening methods suffer from low sample throughput and lack of abilities of mimicking the 3D microenvironment of mammalian tissues. The poor performance of anti-cancer drugs limits the efficacy at controlling the complex disease system like cancer. Systematic studies of apoptotic signaling pathways can be prominent approaches for searching active and effective treatments with less drug resistance. Hence, innovative bio-devices are needed to represent tumor microenvironment to understand the molecular signatures of apoptosis for testing new anticancer therapies targeting apoptosis. Our novel 3D MLC design is the prototype of a high-throughput drug screening platform targeting apoptotic signaling pathways.

scholarly journals The Fabrication and Application Mechanism of Microfluidic Systems for High Throughput Biomedical Screening: A Review

Micromachines ◽  
2020 ◽  
Vol 11 (3) ◽  
pp. 297 ◽  
Author(s):  
Kena Song ◽  
Guoqiang Li ◽  
Xiangyang Zu ◽  
Zhe Du ◽  
Liyu Liu ◽  
...  
Keyword(s):  
High Throughput ◽  
New Technologies ◽  
Biomedical Application ◽  
Raw Materials ◽  
Physical Structure ◽  
Microfluidic System ◽  
Microfluidic Chips ◽  
Microfluidic Systems ◽  
Microfluidic Technology

Microfluidic systems have been widely explored based on microfluidic technology, and it has been widely used for biomedical screening. The key parts are the fabrication of the base scaffold, the construction of the matrix environment in the 3D system, and the application mechanism. In recent years, a variety of new materials have emerged, meanwhile, some new technologies have been developed. In this review, we highlight the properties of high throughput and the biomedical application of the microfluidic chip and focus on the recent progress of the fabrication and application mechanism. The emergence of various biocompatible materials has provided more available raw materials for microfluidic chips. The material is not confined to polydimethylsiloxane (PDMS) and the extracellular microenvironment is not limited by a natural matrix. The mechanism is also developed in diverse ways, including its special physical structure and external field effects, such as dielectrophoresis, magnetophoresis, and acoustophoresis. Furthermore, the cell/organ-based microfluidic system provides a new platform for drug screening due to imitating the anatomic and physiologic properties in vivo. Although microfluidic technology is currently mostly in the laboratory stage, it has great potential for commercial applications in the future.

scholarly journals Microfluidic modelling of the tumor microenvironment for anti-cancer drug development

Lab on a Chip ◽  
2019 ◽  
Vol 19 (3) ◽  
pp. 369-386 ◽  
Author(s):  
Menglin Shang ◽  
Ren Hao Soon ◽  
Chwee Teck Lim ◽  
Bee Luan Khoo ◽  
Jongyoon Han
Keyword(s):  
Tumor Microenvironment ◽  
Drug Development ◽  
Tumor Model ◽  
Cancer Drug ◽  
Microfluidic Systems ◽  
Anti Cancer

Microfluidic tumor model has the unique advantage of recapitulating tumor microenvironment in a comparatively easier and representative fashion. In this review, we aim to focus more on the possibility of generating clinically actionable information from these microfluidic systems, not just scientific insight.

Cell sheet-based multilayered liver tumor models for anti-cancer drug screening

2017 ◽  
Vol 40 (2) ◽  
pp. 427-435 ◽  
Author(s):  
Jianing Yang ◽  
Shengjun Zhao ◽  
Yunfei Ji ◽  
Lili Zhao ◽  
Qingzhu Kong ◽  
...  
Keyword(s):  
Drug Screening ◽  
Liver Tumor ◽  
Cell Sheet ◽  
Cancer Drug ◽  
Tumor Models ◽  
Anti Cancer

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4879-4879
Author(s):  
Myoung Woo Lee ◽  
Hye Jin Kim ◽  
Dae Seong Kim ◽  
Meong Hi Son ◽  
Soo Hyun Lee ◽  
...  
Keyword(s):  
Animal Model ◽  
Mouse Model ◽  
Drug Screening ◽  
Scid Mouse ◽  
Lymphoblastic Leukemia ◽  
Cancer Drug ◽  
Screening System ◽  
Bioluminescent Signal ◽  
Anti Cancer

Abstract Abstract 4879 Background. A hematological malignant animal model is an essential tool for evaluating efficacy of anti-cancer drugs and elucidating underlying mechanism of leukemogenesis. Intraperitoneal (IP) and intravenous (IV) xenograft of acute lymphoblastic leukemia (ALL) cells have limited capacity as in vivo anti-cancer drug screening system. Purpose. In this study, we aimed to establish an ALL animal model using NOD/SCID mouse and evaluate efficiency and sensitivity of the model as a preclinical drug screening system. Materials and Methods. Firefly luciferase (fLuc)-gene introduced ALL (ALL/fLuc) cell line and patient-originated ALL cells were transplanted into a tibia of NOD/SCID mouse. We conducted a comparative analysis of intra-bone marrow (IBMT) transplanted leukemia model with IP and IV transplantation of leukemic cells. Results. IBMT of ALL/fLuc cells effectively established a bioluminescent leukemia NOD/SCID mouse model. Upon comparison of IBMT model with IP and IV transplantation models, infusing identical number of ALL/fLuc cells into NOD/SCID mice resulted in IBMT model with evaluable bioluminescent signal, but not in IP and IV models. In IBMT model, bioluminescent signals of ALL/fLuc cells emitted from peripheral blood, tibia and infiltrated organs indicated that leukemia model was established. The changes in these signals' strength reflected dose-dependent cytotoxic effects of vincristine, which allowed leukemia model with evaluable bioluminescent signal to be utilized as a preclinical drug screening system. IBMT leukemia model was also established using primary ALL cells that can provide additional insights for the development of leukemia therapeutics. Conclusion. IBMT of ALL/fLuc cells enables development of leukemia mouse model with the greater bioluminescent sensitivity than IP and IV in NOD/SCID to evaluate candidate for development of anti-cancer drug. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document